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Purpose: Compared with warfarin, the new target-
speciﬁc oral anticoagulant agents may have advan-
tages, such as shorter hospital length of stay, in
patients with nonvalvular atrial ﬁbrillation (NVAF).
The objective of the present study was to assess,
among patients with NVAF, the effects of rivaroxaban
versus warfarin on the number of hospitalization days
and other health care resource utilization in a cohort
of rivaroxaban users and matched warfarin users.
Methods: Data from health care claims dated from
May 2011 to December 2012 from the Humana database
were analyzed. Adult patients newly initiated on treatment
with rivaroxaban or warfarin, with Z2 diagnoses of AF
(ICD-9-CM code 427.31), and without valvular AF were
identiﬁed. Based on propensity score methods, warfarin
recipients were matched 1:1 to rivaroxaban recipients.
The end of the observation period was deﬁned as the end
of data availability, the end of insurance coverage, death,
the date of a switch to another anticoagulant agent,
or day 14 of treatment nonpersistence. The total number
of hospitalization days and other health care resource
utilization parameters (numbers of hospitalizations,Accepted for publication February 2, 2015.
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554emergency department [ED] visits, and outpatient visits)
were evaluated using the method by Lin et al.
Findings: Matches for all rivaroxaban recipients were
found, and the characteristics of the matched groups
(n ¼ 2253 per group) were well balanced. The mean age
of both cohorts was 74 years; 46% were female. The
estimated mean total numbers of hospitalization days
were signiﬁcantly less in rivaroxaban users compared
with those in warfarin users (all-cause, 2.71 vs 3.87 days
[P ¼ 0.032]; AF-related, 2.11 vs 3.02 days [P ¼ 0.014]).
The numbers of outpatient visits were also signiﬁcantly
less (all-cause, 25.26 vs 35.79 visits [P o 0.001]; AF-
related, 5.48 vs 9.06 visits [P o 0.001]). Rivaroxaban
users had a lesser estimated mean number of all-cause
hospitalizations compared with warfarin users (0.55 vs
0.73; P ¼ 0.084), and a signiﬁcantly lesser estimated
mean number of AF-related hospitalizations (0.40 vs
0.57; P ¼ 0.022). The difference in the estimated mean
numbers of all-cause ED visits was not statistically
signiﬁcant between the rivaroxaban and warfarin users.
Implications: In this study conducted in clinical
practice, the estimated mean numbers of hospitalization
days, outpatient visits, and AF-related hospitalizationsScan the QR Code with your phone to obtain
FREE ACCESS to the articles featured in the
Clinical Therapeutics topical updates or text
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F. Laliberte´ et al.associated with rivaroxaban were signiﬁcantly less than
were those associated with warfarin in these patients
with NVAF. The corresponding estimated difference in
all-cause ED visits was not statistically signiﬁcant. (Clin
Ther. 2015;37:554–562) & 2015 The Authors. Pub-
lished by Elsevier HS Journals, Inc.
Key words: anticoagulant agents, atrial ﬁbrillation,
hospitalizations, resource utilization, rivaroxaban,
warfarin.
INTRODUCTION
For several decades, long-term anticoagulation for stroke
prophylaxis, especially with the vitamin K anticoagulant
warfarin, has been the standard of care in patients with
chronic atrial ﬁbrillation (AF).1 AF is the most common
heart rhythm disorder, with an estimated prevalence in the
United States of between 2.7 and 6.1 million cases.2 In
addition, patients with AF have a high risk for
hospitalization, as evidenced by a 4-fold increase in the
risk for cardiovascular disease–related hospitalization and
an 8-fold increase in the risk for multiple cardiovascular
hospitalizations compared with those in control patients.3
The target-speciﬁc oral anticoagulant agents rivar-
oxaban, dabigatran, and apixaban were recently ap-
proved by the US Food and Drug Administration for
the prevention of stroke in patients with nonvalvular
(NV) AF.4–6 These agents have predictable pharmaco-
kinetic properties and minimal food–drug interactions
and do not require frequent prothrombin time interna-
tional normalized ratio monitoring compared with
warfarin.7–9 Recent studies evaluating the impact of
these new agents on the hospital length of stay (LOS)
have reported that patients with NVAF receiving
target-speciﬁc oral anticoagulant agents had a shorter
hospital LOS than did patients using warfarin.10–13
Because AF is a signiﬁcant driver of hospitalizations14
and the choice of anticoagulant agents may affect hospital
LOS, we sought to compare the total number of hospitali-
zation days and other health care resource utilization
parameters in patients with NVAF treated with a direct
factor Xa inhibitor, rivaroxaban, versus a matched sample
of patients with NVAF treated with warfarin, using health
care claims data from the United States.
MATERIALS AND METHODS
Data Source
The present observational analysis was conducted
using data from health insurance claims dated MayMarch 20152011 through December 2012 from the Humana data-
base. The Humana database includes 411.3 million
lives of commercial and Medicare members, covers all
census regions in the United States, and con-
tains information on patients’ demographic character-
istics, enrollment history, inpatient stays, outpatient
visits, emergency department (ED) visits, and other
health care resource utilization. In addition, the Hu-
mana database contains information from pharmacy
and laboratory claims. Data were deidentiﬁed, and data
collection complied with the requirements of the Health
Insurance Portability and Accountability Act. Institu-
tional review board approval of the study protocol was
not required for this retrospective, observational study.
Study Design
A retrospective, matched-cohort design was used for
quantifying the differences in the total numbers of
hospitalization days and other health care resource
utilization parameters between patients with NVAF
receiving rivaroxaban versus those receiving warfarin.
Patients included in the study were newly initiated on
rivaroxaban or warfarin treatment after November 2011
(the time of rivaroxaban approval for NVAF in the
United States), were 18 years of age or older, had at least
6 months of continuous health plan enrollment before
the index date (ie, baseline period), and had at least 2
diagnoses of AF (International Classiﬁcation of Diseases,
Ninth Edition—Clinical Modiﬁcation [ICD-9-CM] code
427.31) during the baseline or the follow-up period.
Patients were excluded if, during the 6-month
baseline period, they were diagnosed with either
valvular involvement (ICD-9-CM 394.x–397.x, 424.x,
746.0x–746.7x, V42.2, or V43.3; Current Procedural
Terminology, 4th Edition [CPT-4] codes 33400–
33478), pregnancy (ICD-9-CM V22, V23, V27, or
630.x–676.x), malignant cancer (ICD-9-CM 140.x–
208.xx or 230.x–234.x), or a transient cause of AF
(ICD-9-CM 415.x or 429.4; CPT-4 33400–33999).
As in 3 recent clinical trials of target-speciﬁc oral
anticoagulant agents (ie, ROCKET AF [Rivaroxaban
Versus Warfarin in Nonvalvular Atrial Fibrillation],15
RE-LY [Dabigatran Versus Warfarin in Patients with
Atrial Fibrillation],16 and ARISTOTLE [Apixaban Versus
Warfarin in Patients with Atrial Fibrillation]17), patients
treated with rivaroxaban after its approval in Novem-
ber 2011 and with previous use of warfarin were
included in the rivaroxaban cohort in the present
study. In each of those Phase III trials, a total of 50%555
Clinical Therapeuticsto 62% of patients had used warfarin before study
enrollment and randomization. Because the results of
the ROCKET-AF trial15 suggested that rivaroxaban
users naive to warfarin experienced better primary
efﬁcacy and tolerability relative to warfarin-exposed
patients, the inclusion of warfarin-experienced pa-
tients in the rivaroxaban cohort likely produced more
conservative estimates of differences between the 2
groups in the present study.
The observation period spanned from the date of the
ﬁrst dispensation of rivaroxaban or warfarin (ie, the
index date) to the earliest among the end of data
availability, end of insurance coverage, death, date of a
switch to another anticoagulant, or day 14 of treatment
nonpersistence (ie, 14 days after the end of the days of
supply of the ﬁrst dispensation for which the next
dispensation of the index medication, if any, was 460
days later). The nonpersistence criterion increased the
certainty that health care resource utilization was eval-
uated only during exposure to the medications of interest.
Study End Points
The primary end point of this study was the total
number of hospitalization days during the observation
period. In addition, other health care resource utiliza-
tion parameters (ie, numbers of hospitalizations,
ED visits, and outpatient visits) were evaluated.
AF-related visits, deﬁned as the number of hospital-
izations and ED/outpatient claims with a primary or
secondary diagnosis of AF, were also evaluated.
Statistical Analysis
Propensity score matching was performed to adjust
for confounding bias. Patients in the warfarin group
were matched 1:1 to patients in the rivaroxaban
group, using random selection among propensity
score calipers of 5%. Propensity scores were calcu-
lated using a multivariate logistic regression model,
incorporating the following baseline characteristics:
age, sex, type of insurance, Charlson Comorbidity
Index, CHADS2 score, CHA2DS2-VASc score, ATRIA
score, HAS-BLED score, baseline health care resource
utilization, baseline costs, the month of the index date,
and speciﬁc comorbidities (Table I).
Patients’ baseline characteristics evaluated during the 6
months before the index date were summarized using
mean (SD) for continuous variables and frequency
(percentage) for categorical variables. Baseline character-
istics were compared between cohorts, using standardized556differences. Baseline characteristics with a standardized
difference ofo10% were considered well balanced.18–20
The total numbers of hospitalization days and other
health care resource utilization parameters (ie, numbers of
hospitalizations, ED visits, and outpatient visits) in
rivaroxaban and warfarin users were reported and
compared using the method of Lin et al21 to account
for death and the censored observation periods of the
patients. To calculate the estimated mean total numbers
of hospitalization days and the other health care resource
utilization parameters using the method by Lin et al,21 the
follow-up period of each patient was partitioned in small
intervals (ie, days in the present study) and the mean
numbers of hospitalization days and other health care
resource utilization parameters were calculated across all
patients still observed (ie, in-plan and not censored) for a
given interval. Thereafter, the mean total numbers of
hospitalization days, hospitalizations, ED visits, and out-
patient visits were estimated as the sum of the Kaplan-
Meier estimators for the probability of surviving at the
start of each interval, multiplied by the mean studied
outcome over the interval, conditional on surviving at the
start of the interval.
The total numbers of hospitalization days and other
health care resource utilization parameters were com-
pared between cohorts using mean differences. Non-
parametric bootstrap procedures with 999 replications
were used for evaluating the CIs of the differences
between the rivaroxaban and warfarin users. Statistical
signiﬁcance was assessed at a signiﬁcance level ofr0.05.
All statistical analyses were conducted using SAS version
9.3 (SAS Institute Inc, Cary, North Carolina).
RESULTS
Patient Characteristics
A total of 2253 rivaroxaban and 10,796 warfarin users
were identiﬁed (Figure 1). All of the rivaroxaban users
were propensity-matched with the same number of
warfarin users to form the study cohorts. Overall, all
baseline characteristics were well balanced (ie, standar-
dized difference o10%) between the rivaroxaban and
warfarin users. The baseline characteristics of the matched
cohorts are summarized in Table I. The mean age of both
cohorts was 74 years, and 46% of patients were female.
All comorbidity index scores were similar between
cohorts, with standardized differences o10%, and the
most prevalent (430%) comorbidities were hypertension,
hyperlipidemia, diabetes, and abdominal surgery. The
mean observation periods were 114.0 and 123.7 days inVolume 37 Number 3
Table I. Baseline demographic and clinical characteristics of the patients in this study of the effects of
rivaroxaban versus warfarin on total number of hospitalization days and other health care resource
utilization in patients with nonvalvular atrial fibrillation (n ¼ 2253 per group).*
Characteristic Rivaroxaban Warfarin
Standardized
Difference,† %
Matching factors
Demographics
Age, y, mean (SD) 74.2 (9.0) 74.5 (8.7) 4.0
Female, no. (%) 1040 (46.2) 1031 (45.8) 0.8
Insurance type, no. (%)
Commercial
POS 73 (3.2) 74 (3.3) 0.2
PPO 72 (3.2) 71 (3.2) 0.3
HMO 55 (2.4) 45 (2.0) 3.0
IMM Metavance 20 (0.9) 20 (0.9) 0
IHMO 2 (0.1) 2 (0.1) 0
Medicare
Medicare PPO 931 (41.3) 934 (41.5) 0.3
Medicare HMO 770 (34.2) 778 (34.5) 0.7
Medicare PFFS 259 (11.5) 257 (11.4) 0.3
Medicare POS 59 (2.6) 59 (2.6) 0
Medicare risk 10 (0.4) 11 (0.5) 0.7
Medicaid 1 (o0.1) 1 (o0.1) 0
Unknown 1 (o0.1) 1 (o0.1) 0
Clinical
Comorbidity index scores, mean [median] (SD)‡
Quan-Charlson Comorbidity Index 1.5 [1.0] (1.6) 1.5 [1.0] (1.6) 0.5
CHADS2 score 2.3 [2.0] (1.3) 2.3 [2.0] (1.3) 1.8
CHA2DS2-VASc score 3.9 [4.0] (1.7) 3.9 [4.0] (1.7) 1.9
ATRIA score 3.3 [3.0] (2.4) 3.3 [3.0] (2.4) 1.4
HAS-BLED score 1.4 [1.0] (0.9) 1.4 [1.0] (0.9) 0.9
Comorbidities and risk factors, no. (%)‡
Hypertension 1919 (85.2) 1932 (85.8) 1.6
Age 470 y 1588 (70.5) 1598 (70.9) 1.0
Hyperlipidemia 1551 (68.8) 1554 (69.0) 0.3
Diabetes 825 (36.6) 837 (37.2) 1.1
Abdominal surgery 704 (31.2) 722 (32.0) 1.7
Heart failure 556 (24.7) 559 (24.8) 0.3
Renal disease 546 (24.2) 541 (24.0) 0.5
COPD 431 (19.1) 439 (19.5) 0.9
Chronic kidney disease 395 (17.5) 390 (17.3) 0.6
Anemia 382 (17.0) 392 (17.4) 1.2
Multiple trauma 375 (16.6) 357 (15.8) 2.2
Other serious infections 332 (14.7) 337 (15.0) 0.6
Cerebrovascular accident (stroke) 331 (14.7) 333 (14.8) 0.3
Obesity 318 (14.1) 309 (13.7) 1.2
(continued)
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Table I. (continued).
Characteristic Rivaroxaban Warfarin
Standardized
Difference,† %
NSAID use 311 (13.8) 282 (12.5) 3.8
Excessive fall risk (Parkinson’s disease, etc.) 309 (13.7) 305 (13.5) 0.5
Depression 224 (9.9) 218 (9.7) 0.9
Drugs 153 (6.8) 150 (6.7) 0.5
Pneumonia 151 (6.7) 159 (7.1) 1.4
Health care resource utilization, mean (SD)‡
Hospitalizations 0.53 (0.99) 0.54 (0.98) 0.9
ED visits 0.44 (0.96) 0.44 (1.21) 0.1
Outpatient visits 12.68 (10.85) 12.43 (11.43) 2.2
Health care costs, year-2012 US $, mean (SD)‡
Hospitalizations 4534 (10,570) 4720 (9989) 1.8
ED visits 452 (1497) 418 (1375) 2.4
Outpatient visits 2922 (5121) 2834 (5584) 1.6
Pharmacy 1498 (2091) 1368 (3177) 4.8
Total health care cost 9406 (12,921) 9341 (13,140) 0.5
Nonmatching factors, mean (SD)
Observation period, d 114.0 (93.9) 123.7 (91.4) 10.5
Dosing patterns
Dispensations per patient 3.3 (2.8) 3.3 (2.9) 1.9
Days of supply per dispensation 37.6 (19.4) 50.2 (26.1) 54.6
COPD ¼ chronic obstructive pulmonary disease; ED ¼ emergency department; HMO ¼ health maintenance organization;
IHMO ¼ individual health maintenance organization; NSAID ¼ nonsteroidal anti-inﬂammatory drug; PFFS ¼ private fee-for-
service; POS ¼ point of service; PPO ¼ preferred provider organization.
*Additional propensity score matching factors not reported in this table include the following variables: month of index date; family
history of cardiovascular disease, myocardial infarction; coagulation defect; hepatic disease; left ventricular dysfunction; history of
venous thromboembolism; thrombocytopenia (low platelet count); thrombophilia; hip, pelvis, or leg fracture; rheumatoid
arthritis; varicose veins; major bleeding; gastrointestinal bleeding; total knee replacement; ethanol abuse; peptic ulcer; central
venous catheter; inﬂammatory bowel disease; antiplatelet use; total hip replacement; treatment with erythropoiesis stimulating
agents; treatment with SERMs; treatment with aromatase inhibitors; genitourinary bleeding; cerebral bleeding; other bleeding;
immobility; spinal cord injury; surgical resection of abdominal or pelvic cancer; bleeding diathesis; contraceptive pill use.
†For continuous variables, the standardized difference was calculated by dividing the absolute difference in means of the warfarin
and the rivaroxaban cohorts by the pooled SD of both groups. The pooled SD is the square root of the mean of the squared
SDs. For categorical variables with 2 levels, the standardized difference was calculated using the equation (Pwarfarin – Privaroxaban)/
√[p(1 – p)], in which P is the respective proportion of participants in each group, and p is (Pwarfarin þ Privaroxaban)/2.
‡Evaluated during the 6-month baseline period.
Clinical Therapeuticsthe rivaroxaban and warfarin groups, respectively
(standardized difference, 10.5%).
Total Number of Hospitalization Days
The estimated total numbers of hospitalization days
in the rivaroxaban and warfarin users are reported in
Figure 2. With regard to all-cause hospitalizations, the
estimated mean total number of hospitalization days558was signiﬁcantly less in the rivaroxaban users, at 2.71
days, compared with 3.87 days in the warfarin users
(estimated mean difference, –1.16 days; P ¼ 0.032).
With regard to AF-related hospitalizations, the esti-
mated total number of hospitalization days was
signiﬁcantly less, by 0.91 days, in the rivaroxaban
users compared with that in the warfarin users (2.11
vs 3.02 days, respectively; P ¼ 0.014).Volume 37 Number 3
Rivaroxaban or warfarin users
after November 2011
N = 139,639
Rivaroxaban Cohort Warfarin Cohort
Initiating rivaroxaban
N = 5257
Warfarin users
N = 134,382
≥180 days of continuous eligibility
N = 4691
≥180 days of continuous eligibility
N = 109,932
Newly initiated (180-day washout period)
N = 39,723
≥2 AF diagnoses
N = 4118
≥2 AF diagnoses
N = 21,142
1865 were excluded 10,346 were excluded
0 were <18 years of age
1387 had valvular involvement
2 were pregnant
599 had malignant cancer
258 had transient causes of AF
0 were <18 years of age
6980 had valvular involvement
24 were pregnant
3440 had malignant cancer
2964 had transient causes of AF
Rivaroxaban users eligible for matching
N = 2253
Warfarin users eligible for matching
N = 10,796
Figure 1. Patient disposition in this study of the effects of rivaroxaban versus warfarin on total number of hospitali-
zation days and other health care resource utilization in patients with nonvalvular atrial fibrillation (AF).
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Table II presents the estimated mean values of health
care resource utilization parameters other than
hospitalization days. The estimated mean number of
all-cause hospitalizations was less in the patients treated
with rivaroxaban, at 0.55 hospitalizations, compared
with that in patients treated with warfarin, at 0.73
hospitalizations (estimated mean difference, –0.18; P ¼
0.084), and the estimated mean number of outpatient
visits was signiﬁcantly less (25.26 vs 35.79 visits,
respectively; estimated difference, –10.53; P o 0.001).
The estimated mean number of all-cause ED visits was
higher in the rivaroxaban users compared with that in
the warfarin users, at 0.92 and 0.72 visits, but the
difference was not statistically signiﬁcant (estimated
mean difference, þ0.19; P ¼ 0.114).
The estimated mean numbers of AF-related hospi-
talizations were 0.40 in the rivaroxaban recipients and
0.57 in warfarin recipients (P ¼ 0.022). The estimated
mean numbers of AF-related outpatient visits wereMarch 20155.48 visits in the rivaroxaban recipients and 9.06 visits
in the warfarin recipients (estimated mean difference,
–3.59; P o 0.001). The estimated mean number of
AF-related ED visits was signiﬁcantly greater in the
rivaroxaban recipients compared with that in the
warfarin recipients, at 0.48 and 0.26 visits, respec-
tively (estimated mean difference, þ0.23, P ¼ 0.004).
DISCUSSION
This retrospective matched-cohort analysis compared
the numbers of hospitalization days and other health
care resource utilization parameters between rivarox-
aban and warfarin recipients with NVAF, using data
from clinical practice. Rivaroxaban was associated
with signiﬁcant 30% reductions in both all-cause and
AF-related estimated total numbers of hospitalization
days compared with those with warfarin treatment.
Corresponding ﬁndings on all-cause and AF-related
outpatient visits were also signiﬁcantly less in patients
treated with rivaroxaban, and rivaroxaban treatment559
Table II. Health care resource utilization with rivaroxaban versus warfarin use in patients with nonvalvular
atrial fibrillation (n ¼ 2253 per group).*
Resource Rivaroxaban, Mean Warfarin, Mean Treatment Difference (95% CI)† P‡
All cause
Hospitalizations 0.55 0.73 –0.18 (–0.40 to 0.03) 0.084
ED visits 0.92 0.72 þ0.19 (–0.04 to 0.45) 0.114
Outpatient visits 25.26 35.79 –10.53 (–13.59 to –7.25) o0.001
AF related
Hospitalizations 0.40 0.57 –0.17 (–0.34 to –0.03) 0.022
ED visits 0.48 0.26 þ0.23 (0.05 to 0.43) 0.004
Outpatient visits 5.48 9.06 –3.59 (–5.15 to –1.98) o0.001
AF ¼ atrial ﬁbrillation; ED ¼ emergency department.
*Calculated using the method by Lin et al.21
†CIs were obtained using nonparametric bootstraps with 999 replications.
‡P values were estimated using the achieved signiﬁcance level, as reported by Efron and Tibshirani.22
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Figure 2. Total numbers of hospitalization days with rivaroxaban versus warfarin use in patients with
nonvalvular atrial fibrillation (n ¼ 2253 per group).
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F. Laliberte´ et al.was also associated with a 29% reduction in the mean
number of all-cause hospitalizations and a signiﬁcant
25% reduction in the estimated number of AF-related
hospitalizations compared with those with warfarin.
Recent studies have reported that patients with NVAF
who used target-speciﬁc oral anticoagulant agents had a
shorter LOS compared with that in patients using
warfarin. Laliberté et al13 studied data from a Premier
database sample of patients with NVAF administered
rivaroxaban or warfarin during a hospitalization and
reported mean LOS values of 4.46 and 5.27 days in
rivaroxaban and warfarin users, respectively, corres-
ponding to a difference in LOS of 0.81 days in favor of
rivaroxaban users (P o 0.001). Similarly, Fonseca et al10
used data from a hospital Charge Details Master database
and reported that patients treated with dabigatran
incurred a shorter LOS than did patients treated with
warfarin (LOS difference, –1.06; P o 0.01). Cowper
et al12 used data from the ARISTOTLE trial to evaluate
the difference in the cumulative LOS between apixaban
and warfarin in a sample of patients with NVAF. They
reported a similar cumulative LOS with apixaban
compared with that in warfarin users in a US cohort
(mean, 1.70 vs 1.94, respectively; P ¼ 0.19). Our data
suggest that the difference in hospital LOS between the
target-speciﬁc oral anticoagulant rivaroxaban and war-
farin found previously also translates into a signiﬁcant
difference in the total number of hospitalization days.
Using data from the ARISTOTLE trial, Cowper
et al12 also reported that the number of hospitalizations
per patient at 2 years was less with apixaban compared
with warfarin (mean, 0.41 vs 0.48, respectively; P ¼
0.05). In the present study, the use of rivaroxaban was
associated with a non-statistically signiﬁcant lesser
estimated mean number of all-cause hospitalizations
compared with that with the use of warfarin (0.55 vs
0.73; P ¼ 0.084). However, the use of rivaroxaban was
associated with a signiﬁcantly lesser estimated mean
number of AF-related hospitalizations compared with
that with the use of warfarin (0.40 vs 0.57; P ¼ 0.022).
Additional research would be warranted to analyze
whether hospitalizations are possibly avoided with the
use of rivaroxaban compared with warfarin.
The objective of the present study was to evaluate, in
clinical practice, health care resource utilization in
patients with NVAF initiated on treatment with rivar-
oxaban or warfarin. The present study thus included all
warfarin users regardless of international normalized
ratio levels and the time in therapeutic range to reﬂectMarch 2015the usage of the therapy in clinical practice and to
evaluate and compare health care resource utilization
between a cohort of patients in whom rivaroxaban
treatment was initiated and a matched cohort of patients
in whom warfarin treatment was initiated.
Study Limitations
Despite the accuracy and completeness of the informa-
tion required by administrative databases for payment
purposes, billing inaccuracies and missing data may still
occur. Second, a general limitation of observational
studies is that adjustments can be made only for
observable factors; adjustments cannot be made for
unmeasured confounders. Third, this study was con-
ducted with data obtained from the time period immedi-
ately after rivaroxaban became available, and utilization
patterns may have changed over time. Last, the observa-
tional design was susceptible to additional potential
biases, such as information or classiﬁcation bias (eg,
identiﬁcation of false-positive or -negative AF events).
Despite these limitations, observational studies that use
statistical techniques to adjust for potential observed
confounding factors through matching techniques provide
valuable information on scenarios from clinical practice.
CONCLUSIONS
In this propensity matched–cohort analysis in patients with
NVAF, the estimated mean total numbers of hospital-
ization days, outpatient visits, and AF-related hospital-
izations were signiﬁcantly less in rivaroxaban-treated
patients compared with those in warfarin-treated patients.
The estimated difference in all-cause ED visits was not
statistically signiﬁcant between the 2 groups. These ﬁnd-
ings suggest that the use of the target-speciﬁc oral anti-
coagulant agent rivaroxaban in patients with NVAF could
potentially lead to beneﬁts for the health care system.
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